Serum <scp><i>Wisteria floribunda</i></scp> agglutinin‐positive Mac‐2‐binding protein evaluates liver function and predicts prognosis in liver cirrhosis

Xu, Wen; Wang, Ze Rui; Zou, Xia; Zhao, Chen; Wang, Rui; Shi, Pei Mei; Yuan, Zong Li; Yang, Fang; Zeng, Xin; Wang, Pei Qin; Sultan, Sakhawat; Zhang, Yan; Xie, Wei

doi:10.1111/1751-2980.12596

Cited by 7 publications

(5 citation statements)

References 49 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…M2BPGi level increases when compensated cirrhosis develops to decompensated cirrhosis [82][83][84]. Therefore, in patients with cirrhosis, high M2BPGi levels indicate a poor prognosis [82, 85, Fig.…”

Section: Utility Of M2bpgi In Cirrhosismentioning

confidence: 99%

“…M2BPGi levels increase as the disease progresses. M2BPGi can be used to assess disease status, such as that of liver fibrosis [31-38, 52-58, 71-75], HCC risk [31, 32, 36, 48-51, 53, 58, 62-69, 79, 104], HCC recurrence risk [92][93][94], liver function [82,[87][88][89][90][91], and prognosis of chronic liver diseases [82][83][84][85][86], with progression of the disease. In one relevant metaanalysis, the sensitivities and specificities for predicting significant fibrosis ( ≥ F2), advanced fibrosis ( ≥ F3), and cirrhosis were 0.690, 0.764, and 0.818 and 0.778, 0.758, and 0.839, respectively [21].…”

Section: Utility Of M2bpgi In Chronic Liver Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

et al. 2021

View full text Add to dashboard Cite

An accurate evaluation of liver fibrosis is clinically important in chronic liver diseases. Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serum marker for liver fibrosis. In this review, we discuss the role of M2BPGi in diagnosing liver fibrosis in chronic hepatitis B and C, chronic hepatitis C after sustained virologic response (SVR), and nonalcoholic fatty liver disease (NAFLD). M2BPGi predicts not only liver fibrosis but also the hepatocellular carcinoma (HCC) development and prognosis in patients with chronic hepatitis B and C, chronic hepatitis C after SVR, NAFLD, and other chronic liver diseases. M2BPGi can also be used to evaluate liver function and prognosis in patients with cirrhosis. M2BPGi levels vary depending on the etiology and the presence or absence of treatment. Therefore, the threshold of M2BPGi for diagnosing liver fibrosis and predicting HCC development has to be adjusted according to the background and treatment status.

show abstract

Section: Utility Of M2bpgi In Cirrhosismentioning

confidence: 99%

Section: Utility Of M2bpgi In Chronic Liver Diseasesmentioning

confidence: 99%

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Recently, M2BPGi has been used for predicting cirrhosis-related outcomes. Published studies have demonstrated that M2BPGi (cutoff values ranged from 3.61 to 6.15 C.O.I) was an independent risk factor for liver-related mortality or all-cause mortality in cirrhotic patients [18,38,39]. Xu et al [39] retrospectively enrolled 197 cirrhotic patients over a median follow-up period of 23 months and showed that M2BPGi was an independent risk factor for liver-related death in patients with HBV infection and independently predicted clinical decompensation in compensated cirrhosis.…”

Section: Discussionmentioning

confidence: 99%

“…Published studies have demonstrated that M2BPGi (cutoff values ranged from 3.61 to 6.15 C.O.I) was an independent risk factor for liver-related mortality or all-cause mortality in cirrhotic patients [18,38,39]. Xu et al [39] retrospectively enrolled 197 cirrhotic patients over a median follow-up period of 23 months and showed that M2BPGi was an independent risk factor for liver-related death in patients with HBV infection and independently predicted clinical decompensation in compensated cirrhosis. In our previous study which enrolled 48 patients with portal hypertension confirmed by HVPG measurement, we found that plasma M2BPGi values correlated with HVPG levels and helped to predict bacterial infections, with cutoff value of 6 C.O.I [19].…”

Section: Discussionmentioning

confidence: 99%

Mac-2-Binding Protein Glycosylation Isomer to Albumin Ratio Predicts Bacterial Infections in Cirrhotic Patients

Wu,

Hsieh,

Lee

et al. 2024

Dig Dis

View full text Add to dashboard Cite

Introduction Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel biomarker for liver fibrosis, but little is known about its role in cirrhosis-associated clinical outcomes. This study aimed to investigate the predictive role of M2BPGi in cirrhosis-associated complications. Methods One hundred and forty-nine cirrhotic patients were retrospectively enrolled. Patients were followed up for one year and cirrhosis-associated clinical events were recorded. Receiver operating characteristic curve (ROC) analysis was used to establish the values of the predictive models for cirrhotic outcomes. and Cox proportional hazards regression models were used to identify predictors of clinical outcomes, Results Sixty (40.3%) patients experienced cirrhosis-associated clinical events and had higher M2BPGi levels compared to those without events (8.7 vs. 5.1 cut-off index, p < 0.001). The most common cirrhosis-associated complications were bacterial infections (24.2%). On ROC analysis, M2BPGi to albumin ratio (M2BPGi/albumin) had comparable discriminant abilities for all cirrhosis-associated events [area under the ROC curve (AUC) = 0.74] compared with M2BPGi, Child-Pugh, Model for End-Stage Liver Disease, Albumin-Bilirubin scores, and neutrophil to lymphocyte ratio and was superior to M2BPGi alone for all bacterial infectious events (AUC = 0.80). Cox regression analysis revealed that the M2BPGi/albumin, but not M2BPGi alone, independently predicted all cirrhosis-associated events [Hazar ratio (HR) = 1.34, p = 0.038] and all bacterial infectious events (HR = 1.51, p = 0.011) within one year. However, M2BPGi/albumin did not predict other cirrhotic complications and transplant free survival. Discussion/Conclusion M2BPGi/albumin might serve as a potential prognostic indicator for patients with cirrhosis, particularly for predicting bacterial infections.

show abstract

“…Additionally, previous studies have demonstrated that plasma M2BPGi levels were higher in patients with decompensated cirrhosis and higher plasma M2BPGi level was an independent risk factor for liver-related mortality or all-cause mortality in cirrhotic patients [ 21 – 24 ]. Nevertheless, in our studies, we found that M2BPGi did not show a predictive value for all-cause mortality and occurrence of cirrhosis-related complications, including SBP, hepatic encephalopathy, variceal bleeding, hepatorenal syndrome during the follow-up period.…”

Section: Discussionmentioning

confidence: 99%

Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients

Hsieh

Lee

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

Objectives Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel plasma biomarker for liver fibrosis, but less is known about its role in portal hypertension. We aimed to evaluate the association between M2BPGi and hepatic venous pressure gradient (HVPG) and to investigate its predictive value on prognosis of cirrhotic patients. Methods Forty-eight cirrhotic patients who underwent HVPG measurement in Taipei Veterans General hospital were retrospectively enrolled. The Spearman’s correlation test was used to analyze the correlation between plasma M2BPGi levels and HVPG and other parameters. Cox proportional hazards regression models were used to identify predictors for clinical outcomes. Results Plasma M2BPGi levels were higher in cirrhotic patients than healthy subjects and significantly correlated with HVPG levels (rs = 0.45, p = 0.001). On multivariate Cox regression analysis, higher plasma M2BPGi levels [≥ 6 cut-off index (C.O.I)] did not predict mortality within five years for cirrhotic patients and the result was similar in patients without hepatocellular carcinoma. Interestingly, M2BPGi ≥ 6 C.O.I was a potential predictor of bacterial infection within five years [Hazar ratio (HR) = 4.51, p = 0.003]. However, M2BPGi failed to predict occurrence of other cirrhosis-related complications, including variceal bleeding, ascites formation, spontaneous bacterial peritonitis, hepatorenal syndrome and hepatic encephalopathy. Conclusion Plasma M2BPGi levels positively correlated with HVPG and higher serum M2BPGi levels might have a potential role in predicting development of bacterial infection for cirrhotic patients with portal hypertension.

show abstract

Serum Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein evaluates liver function and predicts prognosis in liver cirrhosis

Abstract: Serum WFA -M2BP is a reliable predictor of liver function and prognosis in LC and could be incorporated into clinical surveillance strategies for LC patients, especially those with HBV infection.

Cited by 7 publications

References 49 publications

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

Mac-2-Binding Protein Glycosylation Isomer to Albumin Ratio Predicts Bacterial Infections in Cirrhotic Patients

Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients

Contact Info

Product

Resources

About